Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination

Cancer Immunol Immunother. 2004 Mar;53(3):249-55. doi: 10.1007/s00262-003-0473-9. Epub 2003 Dec 24.

Abstract

Numerous phase I and II clinical trials testing the safety and immunogenicity of various peptide vaccine formulations based on CTL-defined tumor antigens in cancer patients have been reported during the last 7 years. While specific T-cell responses can be detected in a variable fraction of immunized patients, an even smaller but significant fraction of these patients have objective tumor responses. Efficient therapeutic vaccination should aim at boosting naturally occurring antitumor T- and B-cell responses and at sustaining a large number of tumor antigen specific and fully functional effector T cells at tumor sites. Recent progress in our ability to quantitatively and qualitatively monitor tumor antigen specific CD8 T-cell responses will greatly help in making rapid progress in this field.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antigens, Neoplasm / immunology*
  • Cancer Vaccines / immunology*
  • Clinical Trials, Phase I as Topic
  • Humans
  • Neoplasms / therapy*
  • T-Lymphocytes, Cytotoxic / immunology*
  • Vaccination

Substances

  • Antigens, Neoplasm
  • Cancer Vaccines